Targeting the CRMP2-Ca2+ Channel Complex for Abortive Treatment of Migraine and Posttraumatic Headache
Technical Report,01 Sep 2016,31 Aug 2017
University of Arizona Tucson United States
Pagination or Media Count:
Migraine is one of the worlds most common neurological disorders. Current acute migraine treatments have sub-optimal efficacy and new therapeutic options are needed. Approaches targeting calcitonin gene related peptide CGRP signaling are clinically effective but small molecule antagonists have not been advanced due to toxicity. In this study, we explored the axonal growthspecification collapsin response mediator protein 2 CRMP2 as a novel druggable target for inhibiting CGRP release and for potential relevance for treatment of migraine pain and post-traumatic headache.